Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAT-2645 in Advanced or Metastatic Ovarian Cancer
NCT07652073Phase 2Not yet recruiting
- Sponsor
- Danatlas Pharmaceutical Inc.
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
A Phase 2 trial of DAT-2645 in ovarian cancer, sponsored by Danatlas Pharmaceutical Inc.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
DAT-2645
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07652073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652073.